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INTRODUCTION
Lung cancer is the most common cause of cancer
death in developed countries (1). Despite advances
in the detection and treatment of many cancers lead-
ing to improvements in the 5-year survival rate, the
survival rate for lung cancer continues to be 15%
(2). The main reason for the continued low survival
rate for lung cancer patients is that tumors are found
at late invasive stages, when the options for treat-
ment are mostly palliative. Thus, to significantly re-
duce mortality in lung cancer, detection and treat-
ment at earlier stages is essential. Recent advances
in endoscopic technology such as autofluorescence
bronchoscopy (AFB) have been reported to improve
the early detection of premalignant and malignant
bronchial lesions in high-risk individuals (3, 4). In
this report, we demonstrate the efficacy of AFB
which is a novel modality for the early detection of
bronchial premalignant and malignant lesions.
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MATERIALS AND METHODS
Autofluorescence bronchoscopy
An AFB system (SAFE-1000, Asahi Pentax Co.,
Tokyo, Japan) was used in this study (Fig. 1). This
system is composed of a camera unit, fiberoptic
bronchoscope, excitation light source, filing system
and peripherals. The white light from the xenon
lamp is passed through a cut filter and then through
an excitation filter which specifically passes 420-
480 nm excitation light. The excitation light is then
transmitted via a light guide to the target area. Im-
ages obtained with an objective lens are transmitted
via a fiberoptic image guide back to the eyepiece
of the endoscope and guided through the prism to
the fluorescence filter which specifically passes a
490-590 nm fluorescence signal. The selected sig-
nal is then amplified by the image intensifier and by
means of a video camera, it appears as a fluorescent
image on the monitor. Abnormal mucosa shows a
cold image due to the lack of autofluorescence. It
is easy to change between white light and excitation
blue light using the changeover switch on the cam-
era unit. This system is also compact and easy to
handle.
Subjects
The criteria for enrollment in this study were as
follows : 1) patients followed after lung cancer ther-
apy, 2) patients with radiologically suspected lung
cancer, 3) heavy smokers with respiratory symptom,
4) patients with sputum cytology suspicious or posi-
tive for malignancy without chest abnormal shadow.
From November 2000 through March 2004, 123 sub-
jects were evaluated.
Procedure of bronchoscopy
Conventional white light bronchoscopy (WLB)
(BF-240, Olympus Optical Co., Tokyo, Japan) was
first performed under local anesthesia during which
abnormal areas were recorded for subsequent bi-
opsy. Then, AFB was performed and biopsy speci-
mens for pathologic examination were taken from
all suspicious or abnormal areas discovered by WLB,
AFB, or both. In addition, one or more biopsies were
performed in normal areas.
Pathological examination
Bronchial biopsy specimens were fixed in forma-
lin, embedded in paraffin and stained with hema-
toxylin and eosin for histological examination. The
biopsy slides were evaluated by a pathologist ac-
cording to recent World Health Organization crite-
ria. In the present study, lesions in the bronchi were
divided into the following three categories accord-
ing to histopathological diagnosis ; 1) No malig-
nancy : normal epithelium and bronchitis, 2) prema-
lignant lesion : squamous metaplasia and squamous
dysplasia, 3) malignancy : carcinoma in situ and in-
vasive cancer.
Statistical Analysis
The chi-square test was used to evaluate the sig-
nificance of differences between the WLB group
and WLB+AFB group. P -values of0.05 were con-
sidered statistically significant.
Fig. 1 The autofluorescence bronchoscope, SAFE-1000.
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RESULTS
The characteristics of the participants are shown
in Table 1. Among 123 patients, there were 114 men
and 9 women with a mean age of 68 years (range,
25 to 83 years). Forty-five patients were followed
after therapy for lung cancer ; 40 were suspected to
have lung cancer based on their symptoms, smoking
history and/or chest abnormal shadow ; 23 were
heavy smokers with respiratory symptom ; 10 had
abnormal sputum cytology without chest abnormal
shadow ; 4 were others (Table 2). One hundred fif-
teen patients (93.5%) were current or former smokers
with a mean Brinkmen Index of 1114. A total of 282
biopsy specimens were obtained. The pathologic di-
agnoses of these specimens were as follows : normal
epithelium in 129 (45.7%) ; bronchitis in 60 (21.3%) ;
squamous metaplasia in 37 (13.1%) ; squamous dys-
plasia in 10 (3.5%) ; carcinoma in situ in 3 (1.1%) ;
invasive cancer in 43 (15.2%). Thus, 93 biopsy speci-
mens (33.0%) were premalignant or malignant le-
sions (Table 3). Definite diagnoses were yielded in
all patients histologically and/or clinically (Table 4).
Ninety-five (77.2%) were diagnosed as malignancies,
most of which were lung cancer. WLB alone de-
tected 71 of 93 premalignant (squamous metapla-
sia, squamous dysplasia) and malignant (carcinoma
in situ , invasive cancer) lesions. With the addition
of AFB, 90 of 93 lesions were detected, that is, 19
lesions were discovered only by AFB. The sensitiv-
ity of WLB+AFB to detect premalignant and malig-
nant lesions (96.8%) was significantly higher than
WLB alone (76.3%). Similarly, the negative predic-
tive value of WLB+AFB (97.2%) was also signifi-
cantly higher than WLB alone (83.1%) as shown in
Table 5. Moreover, the sensitivity of WLB+AFB to
detect premalignant lesions (95.7%) was significantly
higher than WLB alone (59.6%), whereas there was
no significant difference between WLB+AFB and
WLB alone to detect non-malignant and malignant
lesions (Table 6). These findings strongly suggested
the efficacy of AFB to improve the detection rate of
premalignant bronchial lesions in high-risk individu-
als.
On the other hand, previous reports have demon-
strated that the specificity of AFB to detect prema-
lignant and malignant lesions was relatively low and
these was no significant difference with WLB alone
(3, 4). In the present study, the specificity and posi-
tive predictive value of WLB+AFB were not signifi-
Table 4. Final diagnosis of the patients enrolled in this study.
diagnosis
malignancy 95 (77.2%)
lung cancer 86
esophageal cancer 3
other malignancies 6
benign lung disease 15 ( 12.2%)
chronic obstructive pulmonary disease 6
interstitial pneumonia 3
middle lobe syndrome 2
other benign lung diseases 4
infectious disease 12 ( 9.8%)
bronchopneumonia 8
pulmonary tuberculosis 2
other infectious diseases 2
idiopathic bronchial bleeding 1 ( 0.8%)
total 123
Table 3. Pathological diagnosis of the biopsied specimens.
histology
invasive cancer 43 (15.2%)
carcinoma in situ 3 ( 1.1%)
squamous dysplasia 10 ( 3.5%)
squamous metaplasia 37 (13.1%)
bronchitis 60 (21.3%)
normal epithelium 129 (45.7%)
total 282
Table 2. Patients examined with autofluorescence broncho-
scopy.
purpose of examination
follow up after lung cancer therapy 45 (36.6%)
further examination for chest abnormal shadow 40 (32.5%)
heavy smoker with respiratory symptom 23 (18.7%)
sputum cytology suspicious or positive for malignancy 10 ( 8.1%)
hemosputum and others 5 ( 4.1%)
total 123
Table 1. Patient Characteristics.
Gender male 114 (92.7%)
female 9 ( 7.3%)
Age mean 68
range 25-83
Smoking History smoker 115 (93.5%)
non-smoker 8 ( 6.5%)
Brinkman Index mean 1114
range 0-3120
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cantly different from WLB alone (Table 5) in accor-
dance with previous reports.
In the present study, the addition of AFB to stan-
dard WLB was feasible. There were no adverse
events related to the use of this device.
DISCUSSION
Lung cancer has become the most common cause
of all deaths from cancer and the mortality rate of
lung cancer is still increasing. Diagnosis and resec-
tion of lung cancer at an early stage are considered
to be effective based on dramatically improved sur-
vival rates for resected patients with no surgery (5) ;
however, only a minority of patients are diagnosed
at these curable stages, because of the limitations
of radiographic technology, the lack of specific symp-
toms at an early stage of the disease, and no cur-
rently available validated screening test (6).
Advances in endoscopic technology such as AFB
have recently improved the detection of premalig-
nant and malignant bronchial lesions in high-risk
individuals (7-9). We have also reported that the pre-
cise location of malignant lesions was clearly de-
tected as a defect of autofluorescence by inspection
with AFB, whereas it was quite difficult by inspec-
tion with conventional WLB alone (Fig. 2). Accord-
ing to a previous report, the sensitivity of the bi-
opsy proved that premalignant lesions detected by
white-light bronchoscopy alone was 61.2%, whereas
it was significantly increased to 89.8% with the ad-
dition of AFB (9). Among AFBs, we have been us-
ing the SAFE-1000 system since November 2000.
The advantages of this system are as follows : 1) it
uses a simple device such as a standard xenon lamp
with a filter, rather than a laser, 2) it is more port-
able than the LIFE  lung system (10).
In the present study, the sensitivity for the detec-
tion of bronchial premalignant and malignant lesions
was significantly higher by means of WLB+AFB
(96.8%) than WLB alone (76.3%), according to pre-
vious reports. Similarly, the negative predictive value
of WLB+AFB (97.2%) was also significantly more
elevated than WLB alone (83.1%). Moreover, the
sensitivity for the detection of bronchial premalig-
nant lesions was extremely higher by means of WLB
+AFB (95.7%) than WLB alone (59.6%), whereas
there was no significant difference between WLB
+AFB and WLB alone for the detection of non-
malignant and malignant lesions. These findings
strongly suggested the efficacy of AFB to improve
the detection rate of premalignant bronchial lesions
in high-risk individuals.
Little is known about the natural history of pre-
malignant bronchial lesions in high-risk individuals.
Bota, et al. have reported the alteration of prema-
lignant bronchial lesions followed for 2 years with
AFB (11). During 2 years, 6 of 36 normal epithelia
became dysplastic ; 47 of 152 metaplasia evolved to
low-grade dysplasia, two progressed to carcinoma
in situ , and one to invasive cancer ; 6 of 169 low-
grade epithelial lesions progressed to persistent
severe dysplasia ; 10 of 27 severe dysplastic lesions
and 28 of 32 carcinoma in situ progressed. They
recommended that low-grade epithelial lesions, such
Table 5. Comparison of diagnostic rate between WLB with WLB+AFB for premalignant and malignant lesions.
statistics WLB WLB+AFB
sensitivity (%) 76.3 (71/93) 96.8* (90/93)
specificity (%) 57.1 (108/189) 56.1 (106/189)
positive predictive value (%) 46.7 (71/152) 52.1 (90/173)
negative predictive value (%) 83.1 (108/130) 97.2* (106/109)
WLB : white light bronchoscopy, AFB : autofluorescence bronchoscopy, premalignant lesion : squamous metaplasia, squamous dys-
plasia, malignant lesion : carcinoma in situ , invasive cancer
*p0.05 compared with WLB group.
Table 6. Comparison of sensitivity for the diagnosis between WLB with WLB+AFB in each group.
pathological diagnosis WLB WLB+AFB
no malignacy 42.9 (81/189) 43.9 (83/189)
pre-malignant lesion 59.6 (28/47) 95.7* (45/47)
malignancy 93.5 (43/46) 97.8 (45/46)
WLB : white light bronchoscopy, AFB : autofluorescence bronchoscopy, no malignancy : normal epithelium, bronchitis, premalig-
nant lesion : squamous metaplasia, squamous dysplasia, malignancy : carcinoma in situ , invasive cancer
*p0.05 compared with WLB group.
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as squamous metaplasia and mild dysplasia, could
be followed carefully with AFB, whereas severe dys-
plasia which persists at 3 months and carcinoma in
situ should be treated immediately. According to
this recommendation, we are following squamous
metaplasia and squamous dysplasia every 3 months
with AFB and appropriate therapies have been per-
formed against carcinoma in situ and invasive can-
cer.
The increased thickening of the bronchial epi-
thelium and increases in blood content or vessel
growth are thought to be involved in areas of ab-
normal autofluorescence irrespective of malignancy.
As chronic inflammatory bronchial lesions due to
bronchial asthma and chronic bronchitis are also
known to reveal increased thickening of the epithe-
lium and blood content, defects of autofluorescence
are frequently observed by inspection with AFB in
these lesions ; therefore, AFB can detect false-positive
lesions in patients with bronchial asthma and chronic
bronchitis. The relatively low specificity of AFB to
distinguish malignancy has been reported as one
of the main disadvantages of AFB (3). For exam-
ple, the specificity of conventional bronchoscopy
alone was 78%, whereas it was 42% with the addi-
tion of AFB (3). Recently, a high magnification bron-
chovideoscope has been developed to overcome this
disadvantage of AFB (12). At sites of abnormal aut-
ofluorescence established by AFB, high magnifica-
tion bronchovideoscopy detects squamous dyspla-
sia more accurately than AFB alone (12). Thus, the
combined use of AFB with high magnification bron-
chovideoscopy may be able to decrease the false-
positive rate detected by AFB alone.
Almost all cases of early-stage lung cancer oc-
cur in current heavy smokers or ex-smokers, many
of whom are not eligible for surgical resection due
to synchronous multiple early-stage lung cancers
and/or smoking-related complications, such as poor
pulmonary function and cardio-vascular diseases ;
Fig. 2 (A) Conventional bronchoscopic findings. Whereas some spotty, reddened lesions were found at the upper division
bronchus of the left lung, the precise location of the tumor was quite difficult to determine. (B) Autofluorescence bronchoscopic find-
ings. The location of the tumor was clearly identified as the defect of autofluorescence by AFB (SAFE-1000) at the bifurcation be-
tween the left B1+2 and B3 bronchi. (C) Histological findings of a transbronchial biopsy specimen obtained at the bifurcation between
the left B1+2 and B3 bronchi (H.E stain,200). A solid growth pattern composed of polymorphic tumorous cells with large and hy-
perchromatic nuclei and partial keratinization was found. Histology was squamous cell carcinoma. The tumor invaded beyond the
basement membrane.
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thus, these cases seem to be good candidates for
bronchial interventions. Photodynamic therapy,
brachytherapy, electrocautery, cryotherapy, and Nd-
YAG laser therapy are therapeutic options available
for the management of endobronchial malignancies.
These bronchial interventions have been reported
to be effective for both progressive and early-stage
lung cancers, especially for the latter (8, 13, 14) ;
however, since it is known that early-stage lung can-
cers even when successfully treated with these bron-
chial interventions sometimes relapse, multicentric,
careful follow-up is required in these patients.
In conclusion, the sensitivity for the detection of
bronchial premalignant lesions was proved to be
extremely higher by means of WLB+AFB than WLB
alone. AFB is a novel modality for the early detec-
tion of bronchial abnormality, especially for bron-
chial premalignant lesions.
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